Cadrenal Therapeutics, Inc. (CVKD): Pangali EV/EBITDA

Data for Cadrenal Therapeutics (CVKD) illustrating price evolution on GURU.Markets shows the metric at 0.00, driven by top management's preparations for new drug trials. The business relies on developing anti-thrombotic agents for kidney pathologies, whose uniqueness guarantees a stable income. Primary growth will be driven by the market launch of an unprecedented innovative anticoagulant for advanced stages of the disease.

For the R&D model of Cadrenal Therapeutics (CVKD), which is based on the transfer of anticoagulant rights, the EV/EBITDA multiple history serves as an indicator of the efficiency of intellectual property capitalization. This ratio compares the total enterprise value, including debt, with operating profit, allowing investors to assess the asset payback period and capital stability in the absence of proprietary manufacturing facilities.